Hormonal
Menopausal hormone therapy (MHT) using estrogens delays the onset of type 2 diabetes in postmenopausal women, primarily by improving insulin sensitivity and glucose effectiveness, though it is not FDA-approved for this indication due to risk-benefit complexity.
If you are postmenopausal and suffering from symptoms, MHT may help prevent type 2 diabetes by improving how your body handles insulin and glucose. However, it is not prescribed solely for diabetes prevention due to other health risks. Discuss with your doctor if the benefits for your specific symptoms outweigh the risks, especially if you are at higher risk for diabetes.
Large randomized controlled trials suggest that menopausal hormone therapy (MHT) using estrogens, delays the onset of type 2 diabetes in women.
Why this rating
Supported by large RCTs (WHI, HERS, PEPI) and meta-analyses, though mechanisms are complex and route-dependent.
Source
Menopausal Hormone Therapy and Type 2 Diabetes Prevention: Evidence, Mechanisms, and Clinical Implications
Franck Mauvais‐Jarvis et al. · Endocrine Reviews · 2017
DOI 10.1210/er.2016-1146
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →